title: Epidemiological and clinical features for cefepime heteroresistant Escherichia coli infections in Southwest China.
abstract: Phenotypic heteroresistance (PHR) is common in a weight of microbes and plays an important role in the evolution of antibiotic resistance. However, PHR to cefepime (FEP-PHR) among invasive Escherichia coli (E. coli) has not been reported. This study aimed to report the characteristics of invasive E. coli with FEP-PHR traits and further to investigate the predisposing factors for its acquisition. A retrospective case-control study was conducted in a teaching hospital in Southwest China. A total of 319 successive and non-duplicate E. coli strains were isolated from blood and other sterile body fluids between July 2011 and August 2013. Among the seventy (70/319, 21.9 %) isolates harboring FEP-PHR traits, 30 (42.9 %) isolates were isolated from blood, 14 (20.0 %) isolates were isolated from bile, and 13 (18.6 %) isolates were isolated from drainage. FEP-PHR isolates were verified by population analysis profile (PAP) assays. Male gender, receipt of total parenteral nutrition, cephalosporins exposure, and production of extended spectrum betalactamases (ESBL) were independent risk factors for the acquisition of invasive E. coli with FEP-PHR traits. Pulsedfield gel electrophoresis (PFGE) revealed clonal diversity among the FEP-PHR isolates. The prevalence of heteroresistance to cefepime among invasive E. coli isolates merits great attention and heteroresistance may lead to the emergence of resistance strains. Therefore, systematical analysis of risk factors, careful interpretation of antibiotic susceptibility results and appropriate prescription of therapeutic strategy could help to prevent misreporting and therapeutic failure.
authors.affiliation: Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, 400016, China.
authors.forename: W
authors.initials: W
authors.lastname: Ma
authors.affiliation: Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, 400016, China.
authors.forename: J
authors.initials: J
authors.lastname: Sun
authors.affiliation: Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, 400016, China.
authors.forename: S
authors.initials: S
authors.lastname: Yang
authors.affiliation: Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, 400016, China. 1309898173@qq.com.
authors.forename: L
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001646:Bile / Q000382:microbiology; D001769:Blood / Q000382:microbiology; D016022:Case-Control Studies; D000077723:Cefepime; D002511:Cephalosporins / Q000494:pharmacology*; D002681:China / Q000453:epidemiology; D004322:Drainage; D016521:Electrophoresis, Gel, Pulsed-Field; D004926:Escherichia coli / Q000145:classification / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000453:epidemiology / Q000382:microbiology* / Q000473:pathology*; D005260:Female; D014644:Genetic Variation; D006784:Hospitals, Teaching; D006801:Humans; D008297:Male; D008875:Middle Aged; D058889:Molecular Typing; D012189:Retrospective Studies; D012307:Risk Factors; D018440:beta-Lactam Resistance
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000077723:Cefepime
references.citation: Antimicrob Agents Chemother. 2014;58(3):1779-81
references.pmid: 24342642
references.citation: Infect Genet Evol. 2014 Oct;27:271-6
references.pmid: 25107431
references.citation: Clin Microbiol Infect. 2014 Jan;20 Suppl 1:1-55
references.pmid: 24329732
references.citation: MBio. 2014 Feb 11;5(1):e00942-13
references.pmid: 24520060
references.citation: Antimicrob Agents Chemother. 2013 Aug;57(8):4010-8
references.pmid: 23752516
references.citation: J Clin Microbiol. 1995 Sep;33(9):2233-9
references.pmid: 7494007
references.citation: Clin Microbiol Rev. 2005 Oct;18(4):657-86
references.pmid: 16223952
references.citation: Chemotherapy. 2011;57(2):134-7
references.pmid: 21454970
references.citation: Ann Surg. 1992 May;215(5):503-11; discussion 511-3
references.pmid: 1616387
references.citation: Antimicrob Agents Chemother. 1994 Mar;38(3):415-21
references.pmid: 8203833
references.citation: Int J Antimicrob Agents. 2012 Sep;40(3):235-8
references.pmid: 22784855
references.citation: Int J Infect Dis. 2011 Nov;15(11):e774-80
references.pmid: 21846591
references.citation: J Antimicrob Chemother. 2013 Sep;68(9):2140-3
references.pmid: 23645586
references.citation: Clin Microbiol Infect. 2015 May;21(5):469.e1-10
references.pmid: 25649300
references.citation: BMC Evol Biol. 2008 Feb 18;8:52
references.pmid: 18282299
references.citation: Clin Microbiol Rev. 2015 Jan;28(1):191-207
references.pmid: 25567227
references.citation: Clin Infect Dis. 2009 Sep 1;49(5):682-90
references.pmid: 19622043
references.citation: J Clin Microbiol. 2012 Mar;50(3):721-6
references.pmid: 22189112
references.citation: Clin Microbiol Infect. 2008 Feb;14(2):101-4
references.pmid: 18093235
references.citation: BMC Infect Dis. 2014 Jun 02;14:298
references.pmid: 24889720
references.citation: Phys Rev E Stat Nonlin Soft Matter Phys. 2010 Jan;81(1 Pt 1):011909
references.pmid: 20365401
references.citation: J Microbiol Immunol Infect. 2011 Oct;44(5):364-8
references.pmid: 21524974
references.citation: Infect Control Hosp Epidemiol. 2013 Jan;34(1):1-14
references.pmid: 23221186
references.citation: Clin Microbiol Rev. 2005 Apr;18(2):306-25
references.pmid: 15831827
references.citation: Nutrients. 2015 Aug 03;7(8):6294-312
references.pmid: 26247961